NVS vs ZBH
Novartis AG vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | NVS | ZBH |
|---|
| AI Score |
73
|
70
|
| Price |
$156.34
|
$96.61
|
| P/E Ratio |
23.66×
|
23.38×
|
| ROE |
30.5%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
69.9%
|
| Debt / Equity |
1.18×
|
0.59×
|
| Dividend Yield |
2.9%
|
1.0%
|
| RSI (14) |
55.8
|
58.9
|
| Beta |
0.46
|
0.468
|
| Expected Upside |
+2.7%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for NVS versus ZBH.
NVS leads by 3 points.
NVS scores 73/100 (Buy) versus ZBH at 70/100 (Buy).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.